Search

everythinglearnresearchcommunity

for

Search:↓

Increased Toll-like receptors in blood cells may contribute to alopecia areata and could be a target for new treatments.

Higher CRHR1 levels in AA patients lead to increased inflammation.

RNase L hinders hair follicle regeneration by altering immune signals.

Inhibiting retinoic acid activates WNT signaling, potentially aiding hair disorder and skin cancer treatments.

Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.

CXCR2 in skin cells promotes tumor growth.

Alopecia areata patients show unique protein activity patterns, suggesting imbalanced signaling pathways.

CS12192 effectively treats alopecia areata with better safety than current options.

Certain RNAs may help diagnose alopecia areata by affecting keratin genes.

Expanding CD4+ Tregs can stop hair loss in alopecia areata.

People with alopecia areata have fewer regulatory T-cells than those with other skin conditions.

CD8+ T cells are involved in alopecia areata and may cause disease relapse.

Skin cells can naturally limit the growth of cancerous changes by balancing cell renewal and differentiation.

Certain gene patterns in breast cancer are linked to how active hormone receptors are and could affect patient survival.

Six key genes can predict bladder cancer outcomes and may serve as prognostic biomarkers.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Basal cell carcinomas may use IDO to protect themselves from the immune system.

IL-18 signaling helps mature Tregs move into the thymus.

IL-17 plays a key role in severe hair loss in chronic alopecia areata.

RCS-01 therapy is safe and may improve skin structure by affecting gene expression.

Increasing Treg cells in the skin does not cure hair loss from alopecia areata in mice.

A mouse model for studying scleroderma in chronic graft-versus-host disease was successfully created.

Alopecia areata patients have more activated T cells in their blood, which may help in developing treatments.

ODC expression in mouse skin and tumors is varied and can be inhibited by retinoic acid or cycloheximide.

Some prostate cancers have gene changes that may affect treatment with certain drugs.

Rapamycin increased survival in mice with severe chronic graft-versus-host disease by expanding regulatory T cells.

HDAC4 and HDAC7 are crucial for Th17 cell development and could be targeted to treat inflammatory diseases.

Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.

A new genetic mutation linked to CARASIL syndrome and small artery disease was found in a Chinese family.

Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.